FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
You may also be interested in...
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
Pharmacists See Challenges, Opportunities In Behind-The-Counter Class
Pharmacy trade groups welcome the possibility of a behind-the-counter class of drugs, but a pharmacy professor and former FDA Nonprescription Drugs Advisory Committee chairman cautions a third class could create more demand than pharmacists are able to manage
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”